Business news – Page 67
-
Business
Cancer Drugs Fund axes 23 treatments
The UK government has cut down the list of cancer therapies it will pay for through the Cancer Drugs Fund
-
BusinessUS regulator reprimands Cepheid for norovirus diagnosis tool quality
Diagnostics firm has 15 days to respond to violations laid out by regulator
-
Business
Novartis to buy experimental MS drug from GSK in $1bn deal
Deal will help to bolster Novartis’s pipeline for neurological disorder treatments
-
Business
FDA takes action to remove biosimilars roadblock
The US Food and Drug Administration proposes system to name biosimilar drugs
-
OpinionA risky business
Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe
-
Opinion
Drugs in a class of their own
New drug types need careful regulation to reward innovation while protecting patients
-
Business
Syngenta fends off Monsanto takeover bid
Unmoving objection to merger leads US giant to drop pursuit
-
BusinessFemale sexual desire drug approved
Concerns raised over efficacy, side effects and use of advocacy campaigning to influence regulatory decisions
-
BusinessIndian pharma under increased regulatory scrutiny
Import bans and tightened rules pose a significant challenge for companies
-
BusinessPorous pills could be largest industrial 3D printing use
US grants first-of-a-kind approval for Aprecia’s epilepsy tablets exploiting porous structure
-
BusinessGreek crisis puts pressure on pharmaceuticals
Public spending cuts and capital restrictions on banks have exacerbated drug supply problems in Greece
-
BusinessNo one should be denied medication
Exclusive interview with Yusuf Hamied, chairman of Indian generic drugmaker Cipla
-
BusinessDeadly chemical blast at Chinese port
Explosion at warehouse in Tianjin kills at least 50 and injures hundreds, while ammonia leak sparks mass evacuations in Nanchong
-
Business
Shire makes hostile bid for Baxalta
Recently spun-out from Baxter, Baxalta is resisting the deal, saying it wants time to prove its true value
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
Business
Berry plastics to buy Avintiv for $2.5bn
Deal helps Berry diversify from food packaging into speciality medical materials
-
Business
AstraZeneca sells off drugs to streamline portfolio
Crohn’s disease and rare thyroid cancer drugs lie outside firm’s renewed strategic focus
-
Business
Lightweight composites drive Solvay to buy Cytec
$5.5bn deal launches Solvay into aerospace materials business
-
OpinionA precision instrument?
Chemists and biologists have different expectations when it comes to data, says Derek Lowe